

Contents lists available at [ScienceDirect](http://ScienceDirect.com)

# Biochimica et Biophysica Acta

journal homepage: [www.elsevier.com/locate/bbamem](http://www.elsevier.com/locate/bbamem)

## Structure-activity analysis of thiourea analogs as inhibitors of UT-A and UT-B urea transporters

Cristina Esteva-Font<sup>a,1</sup>, Puay-Wah Phuan<sup>a,1</sup>, Sujin Lee<sup>a</sup>, Tao Su<sup>a</sup>, Marc O. Anderson<sup>b</sup>, A.S. Verkman<sup>a,\*</sup><sup>a</sup> Departments of Medicine and Physiology, University of California, San Francisco, CA 94143-0521, USA<sup>b</sup> Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, CA 94132-4136, USA

### ARTICLE INFO

#### Article history:

Received 3 October 2014

Received in revised form 10 December 2014

Accepted 9 January 2015

Available online 19 January 2015

#### Keywords:

Urea transporter

Kidney

Diuretic

Thiourea

Structure-activity relationships

### ABSTRACT

Small-molecule inhibitors of urea transporter (UT) proteins in kidney have potential application as novel salt-sparing diuretics. The urea analog dimethylthiourea (DMTU) was recently found to inhibit the UT isoforms UT-A1 (expressed in kidney tubule epithelium) and UT-B (expressed in kidney vasa recta endothelium) with  $IC_{50}$  of 2–3 mM, and was shown to have diuretic action when administered to rats. Here, we measured UT-A1 and UT-B inhibition activity of 36 thiourea analogs, with the goal of identifying more potent and isoform-selective inhibitors, and establishing structure-activity relationships. The analog set systematically explored modifications of substituents on the thiourea including alkyl, heterocycles and phenyl rings, with different steric and electronic features. The analogs had a wide range of inhibition activities and selectivities. The most potent inhibitor, 3-nitrophenyl-thiourea, had an  $IC_{50}$  of ~0.2 mM for inhibition of both UT-A1 and UT-B. Some analogs such as 4-nitrophenyl-thiourea were relatively UT-A1 selective ( $IC_{50}$  1.3 vs. 10 mM), and others such as thioisonicotinamide were UT-B selective ( $IC_{50}$  > 15 vs. 2.8 mM).

© 2015 Elsevier B.V. All rights reserved.

### 1. Introduction

Urea transporter (UT) proteins facilitate the passive transport of urea across cell plasma membranes [1–4]. UTs are expressed mainly in kidney, where they are required for the formation of a concentrated urine by countercurrent multiplication and exchange mechanisms [2, 5, 6]. UT-A isoforms encoded by the *SLC14A2* gene are expressed in kidney tubule epithelial cells and UT-B encoded by the *SLC14A1* gene is expressed in kidney vasa recta endothelial cells [7, 8]. X-ray crystal structures have been solved for a bacterial UT homolog produced by *Desulfovibrio vulgaris* [9] and for bovine UT-B [10]. Studies in UT knock-out mice [11–15] and in rodents administered UT inhibitors [16–18] support the conclusion that UT-A1, the UT isoform expressed at the luminal membrane of tubule epithelial cells in inner medullary collecting duct, is the primary target for diuretic development.

Small-molecule screening from our laboratory has identified inhibitors of UT-A1 and UT-B with a wide range of selectivities [16, 19, 20], which are being characterized and optimized as potential drug candidates. Interestingly, the small urea analog dimethylthiourea (DMTU), which has been administered at high doses in experimental animal

models as a hydroxyl radical scavenger [21, 22], inhibits both UT-A1 and UT-B ( $IC_{50}$  2–3 mM) and has been shown to reduce urinary osmolality in rats and produce a salt-sparing diuresis [23]. Motivated by the DMTU findings, the study here was done to establish structure-activity relationships of thiourea analogs for inhibition of UT-A1 and UT-B urea transport, with the goal of identifying more potent and UT-A1-selective analogs for use as research tools and as potential development candidates. Our strategy, as diagrammed in Fig. 1, was to initially screen symmetrical, close structural analogs of DMTU, which was followed by screening of mono-*N*-substituted, asymmetrical thioureas with greater structural diversity. Further refinement to improve potency was done by modification of the position and nature of substitutions. Compounds were identified with >10-fold improved urea transport inhibition potency over DMTU, as well as compounds with high UT-A1 or UT-B selectivity.

### 2. Material and methods

#### 2.1. Compounds


Unless otherwise specified, urea/thiourea analogs were purchased from Sigma-Aldrich (St. Louis, MO). Compounds **4**, **26** and **27** were purchased from Acros Organics-Fisher Scientific (Pittsburgh, PA); **6** from TCI (Portland, OR); **5**, **9**, **18**, **21** and **25** from Alfa Aesar (Ward Hill, MA); **10** and **28** from Santa Cruz Biotechnology (Dallas, TX) and **25** and **30** from ChemBridge (San Diego, CA). Compound **8** was synthesized as follows [24]: to a solution of *N, N'*-dimethylthiourea (200 mg,

*Abbreviations:* UT, urea transporter; DMTU, dimethylthiourea; MDCK, Madin-Darby canine kidney; AQP1, aquaporin-1

\* Corresponding author at: 1246 Health Sciences East Tower, University of California, San Francisco, CA 94143-0521, USA. Tel.: +1 415 476 8530; fax +1 415 665 3847.

E-mail address: [Alan.Verkman@ucsf.edu](mailto:Alan.Verkman@ucsf.edu) (A.S. Verkman).

<sup>1</sup> Authors contributed equally.



**Fig. 1.** Strategy for identification of thiourea analogs with improved potency.

1.92 mmol) in methanol (2 mL) was added iodomethane (0.24 mL, 3.84 mmol) dropwise and the resulting mixture was refluxed for 1 h and then cooled to 0 °C. The resulting white solid was dissolved in anhydrous methanol (5 mL) and reacted with freshly prepared NaSeH (300 mg, 2.88 mmol) in ethanol (2 mL) overnight. The reaction mixture was neutralized with diluted acetic acid and the solvent was removed under reduced pressure. The resulting mixture was diluted with water, extracted with dichloromethane and the solution dried over anhydrous sodium sulfate. The product was purified by crystallization from dichloromethane solution and afforded **8** as a colorless solid (98 mg, 34%). <sup>1</sup>H NMR (chloroform-*d*) δ 6.60 (brs, 2H), 3.04 (brs, 6H); <sup>13</sup>C NMR (chloroform-*d*) δ 180.2, 31.5. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained in chloroform (CDCl<sub>3</sub>) using a 300 MHz Varian spectrometer referenced to TMS. Chemical shifts are expressed in units of Hertz (Hz). Splitting pattern is designated as brs (broad singlet).

## 2.2. Cell culture

Madin–Darby canine kidney (MDCK) cells stably expressing rat UT-A1, yellow fluorescent protein (YFP)-H148Q/V163S and human aquaporin-1 (AQP1), as described previously [19], were grown in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum, penicillin G (100 U/mL), streptomycin (100 µg/mL), zeocin (500 µg/mL), geneticin (600 µg/mL) and hygromycin B (500 µg/mL) at 37 °C, 5% CO<sub>2</sub>.

## 2.3. UT-A1 inhibition assay

UT-A1 inhibition was measured as described [19]. The stably transfected MDCK cells were plated in 96-well plates at a density of 15,000 cells/well at 37 °C for 24 h prior to assay. Briefly, MDCK-UT-A1-AQP1-YFP cells were incubated for 20 min with test compounds and then subjected to an 800 mM urea gradient during continuous measurement of the YFP fluorescence with a plate reader (model Infinite M1000, Tecan Trading AG, Switzerland). The addition of urea to the triply transfected cells produces a rapid cell shrinking (reduced fluorescence) followed by UT-A1-facilitated cell swelling (fluorescence increase). UT-A1 inhibition increases the initial fluorescence decrease and slows recovery. Percentage UT-A1 inhibition was computed as 100% (F<sub>neg</sub> - F<sub>test</sub>) / (F<sub>neg</sub> - F<sub>pos</sub>), where F is the fluorescence measured 7 s after urea addition of the negative control (F<sub>neg</sub>), test compound (F<sub>test</sub>) and positive control (F<sub>pos</sub>).

## 2.4. Functional studies

Reversibility of UT-A1 inhibition was tested by pre-incubation of MDCK cells with inhibitor at a concentration that inhibits urea transport by ~50% and then washing the cells with PBS prior to assay. The kinetics of UT-A1 inhibition was measured by adding inhibitor (at the same concentration used for the reversibility studies) at different times prior to assay. The urea concentration-dependence of UT-A1 inhibition was studied from inhibitor concentration-response data using different urea gradients from 80 to 1600 mM.

## 2.5. UT-B inhibition measurements


As described [20], whole rat blood was diluted to a hematocrit of ~1.5% in PBS containing 1.25 M acetamide and 5 mM glucose. Red blood cell suspensions were added to microplates containing the test compounds and incubated for 15 min. Cells were then subjected to a rapid hypotonic gradient and their lysis was quantified by absorbance at 710 nm. Phloretin was used as a positive control and percentage erythrocyte lysis was computed as: % lysis = 100% (A<sub>neg</sub> - A<sub>test</sub>) / (A<sub>neg</sub> - A<sub>pos</sub>), where A is the absorbance for the negative control (A<sub>neg</sub>), test compound (A<sub>test</sub>) and positive control (A<sub>pos</sub>) at 710 nm. In some studies, urea permeability in rat erythrocytes was assayed by stopped-flow light scattering using a Hi-Tech Sf-51 instrument (Wiltshire, UK) as described [20]. Briefly, a 200-fold dilution of rat blood cells in PBS was incubated with test compound for 10 min, and then subjected to inwardly directed urea gradient (250–500 mM). After an initial osmotic shrinking phase, the kinetics of increasing cell volume caused by urea influx was measured as the time course of 90° scattered light intensity at 530 nm, with increasing cell volume resulting in reduced scattered light intensity.

## 3. Results

Fig. 2A shows concentration-inhibition data for reference compound DMTU, **1**. UT-A1 inhibition was measured by a cell-based fluorescence assay in which cell volume, measured using an intracellular fluorescent indicator, is measured in response to extracellular DMTU addition (top, left). UT-B inhibition was measured using an erythrocyte lysis assay [20]. IC<sub>50</sub> values for inhibition of UT-A1 and UT-B urea transport were 2–3 mM with near complete inhibition seen at higher concentrations.

Symmetrical, bis-alkyl thiourea analogs with structural similarity to DMTU were tested for UT-A1 and UT-B inhibition activity (Table 1). Minor changes in the DMTU structure, such as replacing dimethyl (DMTU, **1**) with hydrogen (**2**) or diethyl (**4**), resulted in significant loss of UT-A1 and UT-B inhibition activity. Tetramethylthiourea **5**, which contains two additional methyl groups, and cyclic thioureas **6** and **7**, were also inactive. Replacing the sulfur atom in DMTU with oxygen (dimethylurea **3**) resulted in loss of activity, as did replacement with selenium (dimethylselenourea **8**). The loss of UT inhibition activity in dimethylurea may be related to the significant differences between oxygen and sulfur in electronegativity (O = 3.5 Pauling unit, S = 2.5), carbon–oxygen/sulfur bond length (C=O = 1.2 Å, C=S = 1.6 Å) and van der Waals radius (O = 1.52 Å, S = 1.8 Å). The loss of inhibition activity of **8** was unexpected, as sulfur and selenium have similar electronegativity (S = 2.5, Se = 2.4), and van der Waals radius (S = 1.8 Å, Se = 1.9 Å); however, the significant difference in polarizability of sulfur and selenium (S = 2.9 Å, Se = 3.8 Å) and slightly elongated carbon–selenium bond length (C=S = 1.6 Å, C=Se = 1.86 Å) [25] could account for its loss of activity.

As the symmetrical thiourea analogs examined above were not active, we next tested a series of asymmetrical mono-substituted thioureas. IC<sub>50</sub> values are summarized in Table 2 and concentration–inhibition data for selected compounds is shown in Fig. 2A. This











**Fig. 2.** Urea transport inhibition by thiourea analogs. A. (top) UT-A1 concentration-inhibition curves for compounds 1 and 18 (bottom). Concentration-inhibition data for UT-A1 and UT-B of thiourea analogs 1, 16, 18 and 26. B. Concentration-inhibition data for UT-A1 and UT-B of thiourea analogs 31, 32, 33, 35 and 36.

included phenylthiourea **9**, heterocyclic thioureas **10–11**, and unsaturated cyclohexylthiourea **12**, which each inhibited UT-A1 and UT-B with potencies comparable to DMTU. Encouraged by these results, we further tested phenyl rings with different steric and electronic properties, including halide (**13–15**), electron-withdrawing (**16–18**), electron-donating (**19–20**) and sterically crowded di-

tri-substitutions (**21–24**). Analogs with electron-withdrawing groups, 4-nitrophenylthiourea **18** and 3,4-dichlorophenylthiourea **21**, gave the best  $IC_{50}$  of 1.3 and 1.5 mM, respectively. Substitution at the 2-position on the phenyl ring resulted in loss of activity as seen in thiourea analogs **22–24**. Analogs with electron-donating groups, such as methoxy and dimethylamino (**19–20**), were inactive. Also, an additional methylene

**Table 1**  
Structure-activity analysis of symmetrical DMTU analogs.

Inhibitor	Structure	UT-A1 $IC_{50}$ (mM)	UT-B $IC_{50}$ (mM)
1		$6.6 \pm 0.4$	$3.9 \pm 0.6$
2		>25	>25
3		$22 \pm 1$	$14 \pm 2$
4		>25	$17 \pm 2$
5		>25	>25
6		>15	$13 \pm 2$
7		>25	>25
8		>25	>25

**Table 2**  
Structure-activity analysis of non-symmetrical DMTU analogs.

Inhibitor	Structure	R	UT-A1 IC <sub>50</sub> (mM)	UT-B IC <sub>50</sub> (mM)
9		Aniline	8.8 ± 0.3	14 ± 1
10		2-Amino-benzimidazole	2.2 ± 0.3	4.7 ± 1.4
11		4-Amino-pyridine	5.3 ± 0.6	1.6 ± 0.3
12		4-Amino-cyclohexyl	3.7 ± 0.2	5.2 ± 0.6
13		4-Fluoro-aniline	13 ± 3	>15
14		4-Chloro-aniline	6.3 ± 1.3	>15
15		4-Bromo-aniline	3.8 ± 0.6	2.4 ± 0.2
16		4-Trifluoromethyl-aniline	15 ± 0.3	>15
17		4-Carboxy-aniline	7.5 ± 1.0	3.6 ± 0.6
18		4-Nitro-aniline	1.3 ± 0.3	10 ± 1
19		4-Methoxy-aniline	>15	>15
20		4-Dimethylamino-aniline	>15	>15
21		3,4-Dichloro-aniline	1.5 ± 0.4	0.4 ± 0.1
22		2,3-Dichloro-aniline	>15	>15
23		2,6-Dichloro-aniline	>15	>15
24		2,4,6-Trichloro-aniline	5.9 ± 1.1	>15
25		4-Chloro-benzylamine	>15	>15
26		4-Pyridine	>15	2.8 ± 0.5
27		3-Pyridine	>25	10 ± 2

group between the amino group and phenyl ring resulted in loss of activity (compare **14** and **25**). Interestingly, thionicotinamide **26** and thioisonicotinamide **27**, which lack the second amino group found in thiourea, were selective for UT-B over UT-A1.

We next focused on the most potent inhibitors, 4-nitrophenylthiourea **18** and 3,4-dichlorophenyl thiourea **21**. *N*-phenyl and *N*-methyl substitution on **18** and **21**, which gave thioureas **28–30**, resulted in similar or reduced potency (Table 3, data for selected compounds shown in Fig. 2B). Changing the position of the nitro-group on phenylthiourea

from para- to meta- (**31**) decreased activity while changing to ortho- (3-nitrophenylthiourea **32**) gave an IC<sub>50</sub> of 0.2 mM for inhibition of both UT-A1 and UT-B, ~6-fold better than **18**. We sought to further improve the potency of **32** by *N*-substitution on the thiourea moiety, including methyl, phenyl, 3-nitrophenyl and semicarbazide groups (**33–36**). However, these substitutions reduced inhibition activity for UT-A1 and UT-B.


Selectivity of the thiourea analogs for UT-A1 vs. UT-B inhibition is summarized in Fig. 3A, which compares reciprocal IC<sub>50</sub> values for inhibition of UT-A1 (abscissa) and UT-B (ordinate) urea transport. Several compounds were UT-A1 selective (red squares), including **14**, **18**, **24** and **28**, while **26** and **31** were UT-B selective (green triangles). The most potent thioureas, **32** and **33**, were non-selective.

Fig. 3B summarizes the structural determinants of compound potency and selectivity. Only thiourea analogs (X = S) were active, as urea (X = O) and selenourea (X = Se) were inactive. Substitution at R<sup>1</sup> in thioureas with an aryl ring bearing electron-withdrawing substituents such as 3,4-dichloro 4-nitro were most active, with 3-nitro giving the best inhibition. In general, various cyclic rings at the R<sup>1</sup> position, such as pyridine, benzimidazole, cyclohexyl and substituted phenyls, also gave good activity. Phenyl rings at R<sup>1</sup> containing electron-donating substituent resulted in loss of activity. For R<sup>2</sup>, unsubstitution (R<sup>2</sup> = H) gave the best inhibition, while increasing the size of the substituent decreased activity (R<sup>2</sup> = methyl, phenyl)

The most potent compound, **32**, was further characterized. Fig. 4A shows similar percentage of inhibition for UT-B and UT-A1, as measured by stopped-flow and plate reader assays, respectively. UT-A1 inhibition by **32** was fully reversible (Fig. 4B) and very rapid (Fig. 4C). The deduced IC<sub>50</sub> using a wide range of urea gradients (80 to 1600 mM) showed a small increase in IC<sub>50</sub> for both **32** and **33**, suggesting a competitive inhibition mechanism (Fig. 4D). The water solubility of **32** and **33** was measured as 0.64 and 0.38 mM, respectively, substantially lower than that of

**Table 3**  
Structure-activity analysis of nitrophenyl and chlorophenyl thiourea analogs.

Inhibitor	Structure	UT-A1 IC <sub>50</sub> (mM)	UT-B IC <sub>50</sub> (mM)
28		2.5 ± 0.5	>15
29		>15	>15
30		2.0 ± 0.6	2.3 ± 0.2
31		9.3 ± 0.7	4.8 ± 1.3
32		0.2 ± 0.1	0.2 ± 0.1
33		0.3 ± 0.2	0.3 ± 0.1
34		0.8 ± 0.2	4.4 ± 0.6
35		1.6 ± 0.9	1.1 ± 0.4
36		3.4 ± 0.7	3.4 ± 0.8



**Fig. 3.** Determinants of compound potency and selectivity. A. Summary of reciprocal IC<sub>50</sub> values for inhibition of rat UT-A1 and rat UT-B for indicated compounds. B. Structural determinants of thioureas for UT-A1 inhibition activity.

DMTU (7.9 M). Compounds **32** and **33** showed no cytotoxicity to MDCK cells at their solubility limit.

#### 4. Discussion


This study was done to identify more potent and selective thiourea analogs than DMTU for inhibition of urea transporters. Minor symmetrical modifications of DMTU resulted in loss of activity. We found that some non-symmetrical substituted arylthiourea analogs gave better inhibition activity than DMTU. Inhibition activity was dependent on the stereo-electronic properties of the substituent, with electron-withdrawing substituent at the meta-position on the aryl ring giving greatest potency.

Two prior studies examined UT-B inhibition by small urea analogs. In an early report, Mayrand and Levitt [26] studied inhibition of erythrocyte urea transport by urea analogs using [<sup>14</sup>C] urea and a fast-flow system. UT-B inhibition was reported of various thiourea analogs at low millimolar concentrations, including phenylthioureas or thionicotinamides, in agreement with the data here. Zhao et al. [27] subsequently reported

that various urea analogs permeate UT-B, albeit less well than urea itself, and that some analogs were weak inhibitors of urea transport.

There are several prior reports on the pharmacological properties of thioureas. DMTU is a hydroxyl radical scavenger that has been used in animals to reduce cellular injury associated with production of hydroxyl radicals. Pre-treatment of rats with DMTU (500 mg/kg) reduced hyperoxia-induced lung edema [28], and DMTU given orally 30 min prior to acute ethanol injury reduced stomach injury [29]. Pharmacological data for other thioureas have also been reported. The ability to taste the bitterness of phenylthiourea **9** (commonly known as phenylthiocarbamide) is a simple genetic trait governed by a pair of alleles, dominant *T* for tasting and recessive *t* for non-tasting [30]. Interestingly, **9** has been used to generate transparent zebrafish by blocking tyrosinase-dependent steps in the melanin pathway [31]. These reports suggest that thioureas are well-tolerated, with minimal cytotoxicity in animals. In general, thioureas are easily synthesized in 2–3 steps from commercially available starting materials for further structure-activity analysis.

One of the reasons for investigating the inhibition potency and selectivity of thiourea analogs was to improve on DMTU, which was shown to have diuretic efficacy in rats and hence potentially be used for



**Fig. 4.** Characterization of **32**. A. Inhibition of rat UT-B urea transport measured in erythrocytes by stopped-flow light scattering (left). UT-A1 concentration-inhibition curves (middle panel). Concentration-inhibition of rat UT-A1 and UT-B (right) (mean ± S.E., n = 3). B. Reversibility. Compounds were incubated (at 0.2 mM) with the triple transfected MDCK cells for 15 min, then washed twice and subjected to UT-A1 inhibition assay. C. Kinetics of UT-A1 inhibition. UT-A1 urea transport measured at different times after addition of 0.2 mM of **32**. D. Concentration-inhibition data for **32** and **33** using 80 and 1600-mM urea gradients (left). IC<sub>50</sub> as a function of urea gradient (right).



proof-of-concept studies in clinically relevant models of edema. The diuretic action of DMTU requires intraperitoneal injection at a very high dose (500 mg/kg in saline) to reach stable levels above its  $IC_{50}$  (>3 mM) in plasma and urine [23]. In preliminary studies, we investigated the potential use of **32** and **33** in rodents. Due to their low water solubility compared to DMTU (soluble to >50 mg/mL in saline) it was necessary to use a different delivery vehicle (5% DMSO, 2.5% polyethylene glycol 400 and 2.4% Tween80 in saline; or 5% dimethylacetamide and 10% solutol or kolliphorHS15 in saline); however, it was not possible to obtain plasma or urine concentrations greater than 0.4 mM. Thus, though several thiooureas identified here had up to 10-fold improved UT inhibition potency compared to DMTU, their low solubility precluded their use as UT inhibitors in animal models.

## Acknowledgements

This study was supported by grants DK101373, DK35124, DK72517, EB00415 and EY13574 from the National Institutes of Health.

## References

- [1] J.M. Sands, Renal urea transporters, *Curr. Opin. Nephrol. Hypertens.* 13 (2004) 525–532.
- [2] C.P. Smith, Mammalian urea transporters, *Exp. Physiol.* 94 (2009) 180–185.
- [3] J.D. Klein, M.A. Blount, J.M. Sands, Urea transport in the kidney, *Compr. Physiol.* 2 (2011) 699–729. <http://dx.doi.org/10.1002/cphy.c100030>.
- [4] C. Esteva-Font, M.O. Anderson, A.S. Verkman, Urea transporter proteins as targets for small-molecule diuretics, *Nat. Rev. Nephrol.* (2014) 1–11. <http://dx.doi.org/10.1038/nrneph.2014.219>.
- [5] J.D. Klein, M.A. Blount, J.M. Sands, Molecular mechanisms of urea transport in health and disease, *Pflügers Arch.* 464 (2012) 561–572.
- [6] R.A. Fenton, Essential role of vasopressin-regulated urea transport processes in the mammalian kidney, *Pflügers Arch.* 458 (2009) 169–177.
- [7] J.J. Doran, J.D. Klein, Y.H. Kim, T.D. Smith, S.D. Kozlowski, R.B. Gunn, J.M. Sands, Tissue distribution of UT-A and UT-B mRNA and protein in rat, *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 290 (2006) R1446–R1459.
- [8] C. Shayakul, B. Clemencon, M.A. Hediger, The urea transporter family (SLC14): physiological, pathological and structural aspects, *Mol. Aspects Med.* 34 (2013) 313–322.
- [9] E.J. Levin, M. Quick, M. Zhou, Crystal structure of a bacterial homologue of the kidney urea transporter, *Nature* 462 (2009) 757–761.
- [10] E.J. Levin, Y. Cao, G. Enkavi, M. Quick, Y. Pan, E. Tajkhorshid, M. Zhou, Structure and permeation mechanism of a mammalian urea transporter, *Proc. Natl. Acad. Sci. U. S. A.* 109 (2012) 11194–11199.
- [11] R.A. Fenton, C.L. Chou, G.S. Stewart, C.P. Smith, M.A. Knepper, Urinary concentrating defect in mice with selective deletion of phloretin-sensitive urea transporters in the renal collecting duct, *Proc. Natl. Acad. Sci. U. S. A.* 101 (2004) 7469–7474.
- [12] R.A. Fenton, A. Flynn, A. Shodeinde, C.P. Smith, J. Schnermann, M.A. Knepper, Renal phenotype of UT-A urea transporter knockout mice, *J. Am. Soc. Nephrol.* 16 (2005) 1583–1592.
- [13] S. Uchida, E. Sohara, T. Rai, M. Ikawa, M. Okabe, S. Sasaki, Impaired urea accumulation in the inner medulla of mice lacking the urea transporter UT-A2, *Mol. Cell. Biol.* 25 (2005) 7357–7363.
- [14] J.D. Klein, O. Frohlich, A.C. Mistry, K.J. Kent, C.F. Martin, J.M. Sands, Transgenic mice expressing UT-A1, but lacking UT-A3, have intact urine concentration ability, *FASEB J.* 27 (2013) 1111–1117 (abstract).
- [15] B. Yang, L. Bankir, A. Gillespie, C.J. Epstein, A.S. Verkman, Urea-selective concentrating defect in transgenic mice lacking urea transporter UT-B, *J. Biol. Chem.* 277 (2002) 10633–10637.
- [16] C. Esteva-Font, O. Cil, P.W. Phuan, T. Su, S. Lee, M.O. Anderson, A.S. Verkman, Diuresis and reduced urinary osmolality in rats produced by small-molecule UT-A-selective urea transport inhibitors, *FASEB J.* (2014) 3878–3890 (pii: fj.14-253872).
- [17] C. Yao, M.O. Anderson, J. Zhang, B. Yang, P.W. Phuan, A.S. Verkman, Triazolothienopyrimidine inhibitors of urea transporter UT-B reduce urine concentration, *J. Am. Soc. Nephrol.* 23 (2012) 1210–1220.
- [18] F. Li, T. Lei, J. Zhu, W. Wang, Y. Sun, J. Chen, Z. Dong, H. Zhou, B. Yang, A novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic, *Kidney Int.* 83 (2013) 1076–1086.
- [19] C. Esteva-Font, P.W. Phuan, M.O. Anderson, A.S. Verkman, A small molecule screen identifies selective inhibitors of urea transporter UT-A, *Chem. Biol.* 20 (2013) 1235–1244.
- [20] M.H. Levin, R. de la Fuente, A.S. Verkman, Urearetics: a small molecule screen yields nanomolar potency inhibitors of urea transporter UT-B, *FASEB J.* 21 (2007) 551–563.
- [21] O. Cil, M. Ertunc, K.S. Gucer, F. Ozaltin, A.B. Iskit, R. Onur, Endothelial dysfunction and increased responses to renal nerve stimulation in rat kidneys during rhabdomyolysis-induced acute renal failure: role of hydroxyl radical, *Ren. Fail.* 34 (2012) 211–220.
- [22] O. Cil, M. Ertunc, R. Onur, The diuretic effect of urea analog dimethylthiourea in female Wistar rats, *Hum. Exp. Toxicol.* 31 (2012) 1050–1055.
- [23] C. Esteva-Font, O. Cil, P.W. Phuan, T. Su, S. Lee, M.O. Anderson, A.S. Verkman, Nanomolar-potency, UT-A-selective Inhibitors of Kidney Tubule Urea Transporters Produce Salt-sparing Diuresis in Rats, 2015. (ASN abstract in press).
- [24] M. Arca, F. Demartin, F.A. Devillanova, F. Isaia, F. Lelj, V. Lippolis, G. Verani, An experimental and theoretical approach to the study of the properties of parabanic acid and related compounds: synthesis and crystal structure of diethylimidazolidine-2-selone-4,5-dione, *Can. J. Chem.* 78 (2000) 1147–1157.
- [25] L.A. Wessjohann, A. Schneider, M. Abbas, W. Brandt, Selenium in chemistry and biochemistry in comparison to sulfur, *Biol. Chem.* 388 (2007) 997–1006.
- [26] R.R. Mayrand, D.G. Levitt, Urea and ethylene glycol-facilitated transport systems in the human red cell membrane. Saturation, competition, and asymmetry, *J. Gen. Physiol.* 81 (1983) 221–237.
- [27] D. Zhao, N.D. Sonawane, M.H. Levin, B. Yang, Comparative transport efficiencies of urea analogues through urea transporter UT-B, *Biochim. Biophys. Acta* 1768 (2007) 1815–1821.
- [28] R.B. Fox, Prevention of granulocyte-mediated oxidant lung injury in rats by a hydroxyl radical scavenger, dimethylthiourea, *J. Clin. Invest.* 74 (1984) 1456–1464.
- [29] G.S. Smith, J.C. Barreto, K.L. Schmidt, M.S. Tornwall, T.A. Miller, Protective effect of dimethylthiourea against mucosal injury in rat stomach. Implications for hydroxyl radical mechanism, *Dig. Dis. Sci.* 37 (1992) 1345–1355.
- [30] S. Wooding, Phenylthiocarbamide: a 75-year adventure in genetics and natural selection, *Genetics* 172 (2006) 2015–2023.
- [31] J. Karlsson, J. Von Hofsten, P.E. Olsson, Generating transparent zebrafish: a refined method to improve detection of gene expression during embryonic development, *Mar. Biotechnol.*(NY) 3 (2001) 522–527.